Treatment of acute infection of total or partial hip arthroplasty with debridement and oral chemotherapy;Tratamiento de la infección aguda de la artroplastia total o parcial de cadera con desbridamiento y régimen antibiótico oral

Medicina Clinica

Volumn 121, Issue 3, 2003, Pages 81-85

  Soriano, Alex ^a   García, Sebastián ^a   Ortega, Mar ^a   Almela, Manel ^a   Gallart, Xavier ^a   Vila, Jordi ^a   Sierra, Josep ^a   Tomas, Xavier ^a   Antonio Martínez, José ^a   Mensa, José ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Debridement and antibiotics, combined; Hip prosthesis; Infection

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; METICILLIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEBRIDEMENT; DRUG EFFICACY; ENTEROCOCCUS; FEMALE; FOLLOW UP; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HIP ARTHROPLASTY; HUMAN; MALE; POSTOPERATIVE INFECTION; SAMPLE; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TISSUE CULTURE; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; BACTERIAL INFECTION; COMPARATIVE STUDY; HIP PROSTHESIS; INFECTION; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; BACTERIAL INFECTIONS; DEBRIDEMENT; FEMALE; HIP PROSTHESIS; HUMANS; MIDDLE AGED; PROSTHESIS-RELATED INFECTIONS; TREATMENT OUTCOME;

EID: 0042326675     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13049259     Document Type: Article

References (24)

1. Schutzer SF, Harris WH. Deep-wound infection after total hip replacement under contemporary aseptic conditions. J Bone Joint Surg (Am) 1988;70:724-7.
2. Fitzgerald RH Jr. Problems associated with the infected total hip arthroplasty. Clin Rheum Dis 1986;12:537-54.
3. Barrack RL. Economics of revision total hip arthroplasty. Clin Orthop 1995;319:209-14.
4. Dreghorn CR, Hamblen DL. Revision arthroplasty: a high price to pay. BMJ 1989;298:648-9.
5. Martí-Valls J, Alonso, J, Lamarca R, Pinto JL, Auleda J, Girvent R, et al. Eficacia y coste de la artroplastia de cadera en siete hospitales de Cataluña, España. Med Clin (Barc) 2000;114(Supl 2):34-9.
6. Goulet JA, Pellicci PM, Brause BD, Salvati EM. Prolonged suppression of infection in total hip arthroplasty. J Arthroplasty 1988;3:109-16.
7. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis 1998;27:711-3.
8. Brandt CM, Sistrunk WW, Duffy MC, Hanssen AD, Steckelberg JM, Ilstrup DM, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997;24:914-9.
9. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee replacement arthroplasty. Risk factors and treatment in sixty-seven cases. J Bone Joint Surg (Am) 1990;72:878-83.
10. Stein A, Bataille JF, Drancourt M, Curvale G, Argenson JN, Groulier P, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral cotrimoxazole (trimethoprim sulfamethoxazole). Antimicrob Agents Chemother 1998;42:3086-91.
11. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997;39: 235-40.
12. Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993;37:1214-8.
13. Javaloyas DM, Monreal PM. Tratamiento antibiótico oral en la osteomielitis bacteriana del adulto: resultados después de dos años de seguimiento. Med Clin (Barc) 1999;113:488-9.
14. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537-41.
15. Ortega M, Soriano A, García S, Almela M, Álvarez M, Tomás X, et al. Perfil de tolerancia y seguridad de levofloxacino en tratamientos prolongados. Rev Esp Quimioterap 2000;13.
16. Lewin CS, Amyes SG. The bactericidal activity of DR-3355, an optically active isomer of ofloxacin. J Med Microbiol 1989;30:227-31.
17. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990;162:96-102.
18. Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus, aureus. J Antimicrob Chemother 1994;33:959-67.
19. Vandecasteele SJ. Early foreign body colonisation induces a metabolic phase variation in Staphylococcus epidermidis. Actas del 41th ICAAC. Chicago, 2001.
20. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-8.
21. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiol cs alone and in combination against Brucella nelitensis at neutral and acidic pHs. Antimcro Agents Chemother 1999;43:1298-300.
22. Morris AB, Kanyok TP, Scott J, Peloquin ChA, Berning SE. Rifamycins. En: Yu VL, Merigar. TC, Barriere SL, editors. Antimicrobial therapy and vaccines. Baltimore: Williams and Wilkins, 1999; p. 901-63.
23. Raymond NJ, Henry J, Workowski KA. Enterococcal arthritis: case report and review. Clin Infect Dis 1995;21:516-22.
24. Stein A, Drancourt M, Raoult D. Ambulatory management of infected orthopedic implants. En: Waldvogel F, Bisno A, editors. Infections associated with indwelling medical devices. Washington DC: ASM Press, 2000; p. 211-30.